Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)
Naval G. Daver
Information is key: why patients need to be empowered to learn about their disease
Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich
How is the landscape of Hodgkin lymphoma therapy changing?
New subtypes of acute lymphoblastic leukemia (ALL) – potential treatment identification by genomics